HC Wainwright Reiterates Buy Rating for Gain Therapeutics (NASDAQ:GANX)

Gain Therapeutics (NASDAQ:GANX)‘s stock had its “buy” rating reiterated by equities research analysts at HC Wainwright in a note issued to investors on Thursday, Benzinga reports. They presently have a $9.00 target price on the stock. HC Wainwright’s target price suggests a potential upside of 182.13% from the company’s previous close.

Other analysts have also recently issued reports about the company. Chardan Capital reiterated a “buy” rating and issued a $6.00 target price on shares of Gain Therapeutics in a report on Wednesday, March 27th. Oppenheimer reiterated an “outperform” rating and issued a $9.00 target price on shares of Gain Therapeutics in a report on Tuesday.

Gain Therapeutics Stock Performance

Gain Therapeutics stock opened at $3.19 on Thursday. The business has a 50 day moving average of $4.04 and a 200-day moving average of $3.44. Gain Therapeutics has a 1 year low of $2.00 and a 1 year high of $5.65. The company has a debt-to-equity ratio of 0.04, a current ratio of 3.59 and a quick ratio of 3.59. The company has a market capitalization of $51.74 million, a P/E ratio of -1.87 and a beta of 0.43.

Gain Therapeutics (NASDAQ:GANX) last released its quarterly earnings data on Tuesday, March 26th. The company reported ($0.29) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.32) by $0.03. On average, equities research analysts predict that Gain Therapeutics will post -1.17 earnings per share for the current year.

Insiders Place Their Bets

In other news, Director Jeffrey Scott Riley bought 30,000 shares of the business’s stock in a transaction that occurred on Thursday, March 28th. The shares were bought at an average cost of $3.86 per share, for a total transaction of $115,800.00. Following the acquisition, the director now directly owns 30,000 shares in the company, valued at $115,800. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 11.00% of the company’s stock.

Gain Therapeutics Company Profile

Gain Therapeutics, Inc, a clinical-stage biotechnology company, engages in the discovery and development of allosteric therapies. Its lead drug candidate, GT-02287 for the treatment of GBA1 Parkinson's disease is being evaluated in a Phase 1 clinical trial. Its drug discovery platform Magellan identifies novel allosteric binding sites on disease-implicated proteins and exploits untapped opportunities, by pinpointing pockets that cannot be found or drugged with current technologies.